PENNSYLVANIA PAIN ATLAS · MEDICAL ASSISTANCE COVERAGE
Show which opioid rule follows every Medicaid card.
Pennsylvania publishes statewide opioid coverage criteria, quantity limits, plan specific rules, prescribing guidance, and monitoring duties. A patient should be able to tell which requirement applies before reaching the pharmacy counter.
The first move: require DHS to publish one current coverage map separating statewide rules from fee for service and managed care differences.
Primary public sources checked September 8, 2026. No denial pattern or plan defect is claimed without operative records.
01 · EXECUTIVE FINDING
Pennsylvania has the pieces. It does not yet present one operating map.
The Department of Human Services publishes statewide preferred drug list clinical guidelines for long acting and short acting opioid analgesics, quantity limits, general prior authorization procedures, forms, and a covered drug search tool. Its public preferred drug materials explain that criteria for drug classes included on the statewide list apply to fee for service and Medical Assistance managed care organizations.
For drugs or products outside the statewide list, fee for service criteria and managed care requirements may differ. That division is legitimate, but it leaves patients and prescribers assembling the controlling rule from several sources.
A statewide program should show which rule is statewide and where the card still changes the answer.
02 · CLASSIFICATION METHOD
Separate clinical guidance from coverage machinery.
- Statewide preferred drug criterion: a coverage requirement applied across fee for service and managed care for an included class.
- Fee for service criterion: a DHS rule that does not necessarily govern managed care.
- Managed care criterion: a plan specific requirement outside the statewide rule.
- Quantity or daily dose limit: a numerical coverage trigger with its own review route.
- Prescribing guideline: clinical guidance that Pennsylvania says supplements rather than replaces individual judgment.
- PDMP duty: a statutory monitoring obligation separate from payment policy.
No item should be called law, Medicaid policy, or private choice until its source and scope are established.
04 · PENNSYLVANIA’S OWN SAFEGUARDS
State materials already warn against mechanical application.
Pennsylvania’s Department of Health says its opioid prescribing guidelines and the federal guideline are intended to supplement, not replace, individual clinical judgment. Its patient advocacy materials also warn that abrupt change after prolonged opioid therapy may put a patient at risk and should involve deliberative case review and discussion.
Act 112 of 2019 separately requires education and a treatment agreement before the first opioid prescription in a single course of treatment for chronic pain. The PDMP creates another distinct layer of monitoring obligations.
- A guideline is not automatically a disciplinary rule.
- A PDMP notification does not prove wrongdoing.
- A treatment agreement duty is not a Medicaid coverage criterion.
- A quantity limit may trigger review without deciding medical necessity by itself.
- Continuity questions should be answered by the actual payer rule and patient specific process.
The requested coverage map preserves these distinctions instead of arguing that safeguards should disappear.
05 · THE EXACT REQUEST
Publish one Pennsylvania opioid coverage map.
DHS should publish a single, version controlled table identifying every opioid analgesic coverage rule and whether it applies statewide, only to fee for service, or separately through each managed care plan.
- Identify the drug class, preferred status, quantity limit, daily dose limit, and prior authorization trigger.
- Link the exact current clinical criterion, form, bulletin, and effective date.
- State which requirement applies to fee for service and which applies to each managed care plan.
- Distinguish a pharmacy edit, documentation request, medical necessity review, and final adverse determination.
- Identify reviewer authority, required evidence, exception or override, emergency supply, continuity protection, and appeal route.
- Publish the revision history and the authority that approved each statewide criterion.
- Link plan specific criteria from the same state table when no statewide rule controls.
- Publish aggregate approvals, denials, reversals, and processing times if those records are already maintained.
06 · READY TO USE LANGUAGE
Ask for a map the pharmacy can actually use.
Please publish one current Pennsylvania Medical Assistance opioid coverage table. For every long acting and short acting opioid analgesic rule, identify whether the requirement applies statewide, only to fee for service, or separately through a managed care plan. Include the trigger, criterion, evidence, reviewer, override, emergency supply, continuity procedure, notice, appeal route, effective date, and revision history. Please distinguish clinical guidance and PDMP duties from coverage requirements.
If DHS says the information already exists, ask it to link every required field from one authoritative page. A list of separate bulletins and plan sites is not a complete coverage map.
07 · ACTION SEQUENCE
Start with the state table, then test the plans.
- Day 1: preserve the current statewide preferred drug list, opioid criteria, quantity limits, covered drug results, and general procedures.
- Day 2: send the coverage map request to DHS Pharmacy Services.
- Day 7: identify missing plan links, effective dates, and decision routes.
- Records stage: use focused Right to Know requests for existing criteria, approval records, instructions, and aggregate outcomes.
- Comparison stage: test plan specific rules only where the state map identifies a difference.
- Correction stage: ask the responsible authority to repair a documented inconsistency or inaccessible remedy.
Send records requests to the agency that possesses the records. The Office of Open Records supplies the process and appeal route, but it is not the custodian for every agency record.
08 · MEASURABLE RESULTS
The correct rule should be visible before a prescription is adjudicated.
SCOPE
Every criterion is labeled statewide, fee for service, or plan specific.
DECISION
Trigger, evidence, reviewer, override, and consequence are stated.
CONTINUITY
Emergency supply, ongoing therapy, notice, and appeal paths are usable.
VERSION
Effective dates, approvals, changes, and superseded criteria are preserved.
A general link to a preferred drug list is not completion. Completion means a patient and prescriber can identify the controlling rule for the actual coverage card.
09 · STATE AND FEDERAL CONNECTION
Federal standards matter after Pennsylvania identifies its own rule.
Federal Medicaid law governs drug utilization review, medically necessary coverage, notice, and fair hearing protections. It does not eliminate the need to identify whether a Pennsylvania requirement comes from the statewide list, fee for service administration, or a managed care plan.
First identify the exact state mechanism. Then test its authority, clinical basis, consistency, and remedy.
This order creates a record that state officials, federal reviewers, courts, journalists, and legislators can evaluate without speculation.
10 · ESCALATION AND OFF RAMP
Use Pennsylvania’s own patient centered language.
The Department of Health already tells patients and clinicians that guidance supplements individual judgment and that abrupt change can create risk. DHS can align the coverage record with that principle by making overrides, continuity routes, and plan differences visible.
If the state publishes a complete table and the criteria provide a functioning individualized route, document the result and stop. If the record reveals an unexplained plan difference, missing exception, or mechanical consequence, direct the next request to the authority that owns that defect.
The campaign ends when the rule, card, decision, and remedy can be traced on one public record.
11 · PRIMARY SOURCES
Pennsylvania publishes enough to build the map.
- DHS Pharmacy Services
- DHS Prior Authorization Clinical Guidelines
- Covered Drugs Search Tool
- Pharmacy and Therapeutics Committee
- Pennsylvania Prescribing Guidelines
- Patient Advocacy Program for Professionals
- Pennsylvania PDMP
- Opioid Treatment Agreements
- State Board of Medicine
- Office of Open Records
Verification note: Official sources were checked September 8, 2026. Criteria, forms, plan rules, officials, and filing routes must be checked again before formal action.
12 · THE PENNSYLVANIA POSITION
One program. One visible map of the rules.
Pennsylvania does not need to weaken a lawful safeguard to make its coverage system legible. It needs to show where statewide control ends, where a plan rule begins, and how individualized review can actually be reached.
This is the Oklahoma method applied to Pennsylvania: identify the controlling institution, isolate one public deliverable, preserve legal distinctions, measure the response, and escalate only a proven defect.